Anterior Uveitis pipeline therapeutics constitutes close to 6 molecules
Out of which approximately 6 molecules are developed by Companies. Our latest report Anterior Uveitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Anterior Uveitis Anterior uveitis is an inflammation of the middle layer of the eye, which includes the iris (colored part of the eye) and ciliary body. Symptoms include a red, sore and inflamed eye, blurring of vision, sensitivity to light and a small pupil. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 2 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.
Key Topics Covered:
- Anterior Uveitis Overview
- Therapeutics Development
- Pipeline Products for Anterior Uveitis - Overview
- Pipeline Products for Anterior Uveitis - Comparative Analysis
- Anterior Uveitis - Therapeutics under Development by Companies
- Anterior Uveitis - Therapeutics under Investigation by Universities/Institutes
- Anterior Uveitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Anterior Uveitis - Products under Development by Companies
- Anterior Uveitis - Products under Investigation by Universities/Institutes
- Anterior Uveitis - Companies Involved in Therapeutics Development
- Aciont Inc.
- Aldeyra Therapeutics, Inc.
- EyeGate Pharmaceuticals, Inc.
- KPI Therapeutics, Inc.
- Neuroptis Biotech
For more information about this report visit http://www.researchandmarkets.com/research/4f2w46/anterior_uveitis